My man, he's just projecting.
He can't understand why IMU is performing so badly, so he assumes every biotechnology company is like that.
Look at everything he says about data, management, hand held, and it's all applicable to his situation at IMU.
It takes a special type of person to speculate "Business discussions are ongoing" is a good thing despite the data for HERVaxx being objectively bad, then ignore an entire dataset supporting Bisantrene for anti-cancer effects, say it's worthless, and instead focus on cardioprotection. Even though everyone on this forum knows the IC50 values for anti-cancer effects (FTO inhibition, for example) are very potent and a primary target of Bisantrene.
Cardioprotection thread, page-789
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.73 |
Change
-0.105(5.74%) |
Mkt cap ! $293.8M | |||
| Open | High | Low | Value | Volume |
| $1.82 | $1.82 | $1.70 | $240.3K | 138.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 270 | $1.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.75 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |